Agyany Pharam LTD

Agyany Pharma Ltd. is a biotechnology company based in Jerusalem, Israel, focused on developing new treatments for Parkinson's disease and related disorders, particularly those associated with GBA1 mutations. The company utilizes a scientific approach that involves repurposing existing, well-known generic drugs to target the underlying molecular drivers of disease. Their primary therapeutic candidate, ambroxol, is being investigated for its potential to act as a pharmacological chaperone, correcting enzyme misfolding in the brain, crossing the blood-brain barrier, and reducing toxic protein buildup. This strategy aims to provide a more efficient path to novel therapeutic interventions compared to traditional drug development methods. The leadership team brings extensive experience in rare disease research, biomarker discovery, and international clinical studies.

For patients and healthcare providers, Agyany's focus on GBA1-associated Parkinson's addresses a significant unmet need for disease-modifying therapies in a fast-progressing, genetically defined patient population. By leveraging established scientific insights from Gaucher disease research, the company is conducting clinical trials to validate the safety and efficacy of their pharmacological approach. Their work is centered on translating complex neurological mechanisms into clinical practice, with the goal of improving patient outcomes and offering new hope for individuals affected by Parkinson's disease globally. The company operates as a private limited entity with a commitment to international collaboration and patient-centric innovation in neurodegenerative disease.